See Beyond the Surface: How Cellvizio® Redefines Accuracy for Detecting and Treating Cancers | Byline by Daryl C. Donatelli, MBA, President, U.S. & Head of Global Marketing, Mauna Kea Technologies
For patients facing a potential cancer diagnosis, the heaviest burden isn’t always the treatment; it’s the wait. The wait for clarity. The wait for answers. The wait to know whether something benign could become something more serious. And even today with wearable monitors, AI, robotic surgery, and precision medicine, some cancers still have alarmingly high prevalence and devastatingly poor survival rates[1]. Why? Read on.